3 results
* To assess the safety and tolerability of Ampligen administered intranasally in a dosing schedule for 13 days (7 doses) in healthy subjects.* To characterize the mucosal immune response following Ampligen administration over time.
Our overall aim is to measure several distinct MR parameters at 0.047 Tesla, and to use these to derive optimal MRI-protocols in terms of contrast and SNR. The images produced will then be compared with those from the commercial Hyperfine system.…
The primary objective of the safety run-in (phase Ib) is to determine the safety of combination therapy with durvalumab and rintatolimod. The primary objective of the phase II trial is to determine the clinical benefit rate of combination therapy…